Physicians' Academy for Cardiovascular Education

Beneficial effects of SGLT2 inhibitor in diabetic patients with metabolic syndrome

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

Literature - Davies MJ, Merton KW, Vijapurkar U, et al. - Diabetes Metab Syndr Obes. 2017;10:47-55


Canagliflozin, an SGLT2 inhibitor, increases urinary glucose excretion leading to improved glycaemic control, body weight, and blood pressure in type 2 diabetes mellitus (T2DM) patients [1-4]. These improvements suggest that canagliflozin may be an effective treatment for improving the components of metabolic syndrome in T2DM patients, including dyslipidaemia, central obesity, hypertension and glucose intolerance.

In this post-hoc analysis, the effects of canagliflozin versus glimepiride (study 1, on a metformin background) and versus sitagliptin 100 mg (study 2, on a metformin and sulfonylurea background) were evaluated in patients with T2DM and metabolic syndrome [5,6].

Main results


In a post-hoc analysis of two studies, canagliflozin had beneficial effects on body weight, BMI, waist circumference, SBP, DBP and HDL-C compared with glimepiride or sitagliptin in T2DM patients with metabolic syndrome. In the overall study populations, canagliflozin was generally well tolerated, with a higher incidence of genital mycotic infections and osmotic diuresis–related AEs.


Show references

Find this article online at Diabetes Metab Syndr Obes

Share this page with your colleagues and friends: